Bristol-Myers Loses Canadian Court Battle Over Taxol Alternative

Law360, New York (May 20, 2005, 12:00 AM EDT) -- A tiny Canadian drug maker has defeated U.S. drug giant Bristol-Myers Squibb Co. in a five-year patent battle over the right to sell an inexpensive cancer treatment that would compete with the blockbuster chemotherapy treatment Taxol.

As a result of the decision by the Supreme Court of Canada, Biolyse Pharma Corp. will have the right to market a drug that sells for one-third of the listed price for Bristol-Myer's competing drug Taxol.

In a 6-3 decision, the Supreme Court found that although Bristol-Myers had patent protection...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.